HTR2A Gene

HTR2A Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HTR2A — Serotonin Receptor 2A</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HTR2A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>5-Hydroxytryptamine Receptor 2A</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>13q14.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3352" target="_blank">3352</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102468" target="_blank">ENSG00000102468</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28223" target="_blank">P28223</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Schizophrenia](/diseases/schizophrenia), [Depression](/diseases/depression), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cortex, Platelets, Smooth muscle, Olfactory bulb</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/bipolar" style="color:#ef9a9a">Bipolar</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td

HTR2A Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HTR2A — Serotonin Receptor 2A</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HTR2A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>5-Hydroxytryptamine Receptor 2A</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>13q14.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3352" target="_blank">3352</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102468" target="_blank">ENSG00000102468</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28223" target="_blank">P28223</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Schizophrenia](/diseases/schizophrenia), [Depression](/diseases/depression), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cortex, Platelets, Smooth muscle, Olfactory bulb</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/bipolar" style="color:#ef9a9a">Bipolar</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">63 edges</a></td>
</tr>
</table>

HTR2A — Serotonin Receptor 2A

Introduction

Htr2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

HTR2A (5-Hydroxytryptamine Receptor 2A) encodes the 5-HT2A serotonin receptor, a G protein-coupled receptor (GPCR) that activates phospholipase C signaling cascades. It is widely expressed throughout the central nervous system and is the primary molecular target of psychedelic drugs (LSD, psilocybin, DMT) and atypical antipsychotics["@nichols2012"]. The 5-HT2A receptor plays critical roles in mood regulation, cognition, perception, and sleep-wake cycles, making it a key therapeutic target for neuropsychiatric disorders.

Receptor Structure

The HTR2A-encoded protein possesses the classic seven-transmembrane domain structure of GPCRs:

• Extracellular N-terminus: Contains glycosylation sites important for receptor folding and trafficking
• Transmembrane domains: Seven hydrophobic alpha-helices that form the ligand-binding pocket
• Third intracellular loop: Contains the G protein coupling interface
• C-terminal tail: Contains serine/threonine phosphorylation sites for desensitization and arrestin binding

Signal Transduction

HTR2A activates the Gq/11 protein signaling pathway:

• DAG (diacylglycerol) → activates protein kinase C (PKC)
• IP3 (inositol trisphosphate) → releases calcium from ER stores

• Calcium-dependent neuronal excitation
• PKC-mediated phosphorylation of ion channels and transcription factors
• CREB activation and gene expression changes

Normal Physiological Functions

Central Nervous System

• Cortical processing: 5-HT2A receptors in layer V pyramidal [neurons](/entities/neurons) modulate cortical output and plasticity
• Perception: Critical for psychedelic drug effects and normal sensory processing
• Mood regulation: Antagonist activity contributes to antidepressant efficacy
• Sleep-wake cycles: Regulates REM sleep and arousal states
• Thermoregulation: Central 5-HT2A signaling modulates body temperature

Peripheral Tissues

• Platelets: Major serotonin receptor mediating platelet aggregation
• Smooth muscle: Vasoconstriction in blood vessels, gastrointestinal motility
• Olfactory bulb: Modulates olfactory sensory processing

Brain Region Distribution

HTR2A exhibits distinct regional expression patterns:

| Brain Region | Expression Level | Functional Implications |
|--------------|-----------------|----------------------|
| Prefrontal [cortex](/brain-regions/cortex) | High | Cognitive processing, working memory |
| Primary sensory cortex | High | Sensory gating, integration |
| Claustrum | Very high | Consciousness, integration |
| Olfactory bulb | High | Olfactory processing |
| [Hippocampus](/brain-regions/hippocampus) | Moderate | Memory, emotional processing |
| Thalamus | Moderate | Sensory relay modulation |
| Brainstem raphe | Low | Autoregulation |

Disease Associations

Schizophrenia

The 5-HT2A receptor is central to schizophrenia pathophysiology and treatment:

• Atypical antipsychotics: Clozapine, risperidone, olanzapine primarily work through 5-HT2A antagonism
• A/A genotype: rs6313 polymorphism associated with improved treatment response
• Pyramidal neuron dysfunction: Altered 5-HT2A signaling contributes to cortical hypofrontality
• Hallucinations: 5-HT2A overactivation may contribute to psychotic symptoms[@gonzalezmaeso2007]

Major Depressive Disorder

5-HT2A receptors are implicated in depression and antidepressant action:

• Antagon: Trazodone,ist efficacy mirtazapine, and atypical antipsychotics have 5-HT2A antagonist activity
• SSRIs and 5-HT2A: Chronic SSRI use leads to 5-HT2A downregulation correlating with therapeutic response
• Treatment-resistant depression: 5-HT2A agonists may have rapid antidepressant effects (psilocybin trials)[@carhartharris2021]
• Post-SSRI sexual dysfunction: 5-HT2A activation contributes to sexual side effects

Parkinson's Disease

5-HT2A signaling influences both motor and non-motor symptoms:

• L-DOPA-induced dyskinesias: 5-HT2A antagonists reduce dyskinesia severity in preclinical models
• Parkinson's psychosis: 5-HT2A overactivity contributes to visual hallucinations
• Sleep disorders: Altered 5-HT2A signaling affects REM sleep behavior disorder
• Depression in PD: Serotonergic dysfunction including 5-HT2A contributes to mood symptoms[@huot2012]

Alzheimer's Disease

5-HT2A changes are observed throughout AD progression:

• Cortical loss: 5-HT2A receptor density decreases in AD cortex
• Behavioral and psychological symptoms of dementia (BPSD): 5-HT2A alterations contribute to agitation, anxiety, depression
• Amyloid interaction: [Aβ](/proteins/amyloid-beta) oligomers can modulate 5-HT2A signaling
• Therapeutic targeting: 5-HT2A modulators may help manage BPSD

Other Neurological Conditions

• Migraine: 5-HT2A mediates vasoconstriction in migraine treatment (triptans are 5-HT1B/1D agonists)
• Epilepsy: Altered 5-HT2A expression in seizure disorders
• Anxiety disorders: 5-HT2A antagonists have anxiolytic potential

Therapeutic Implications

Current Therapeutics

| Drug Class | Examples | Mechanism | Application |
|-----------|----------|-----------|-------------|
| Atypical antipsychotics | Clozapine, risperidone | 5-HT2A antagonism + D2 antagonism | Schizophrenia, psychosis |
| Antidepressants | Trazodone, mirtazapine | 5-HT2A antagonism | Depression, insomnia |
| Migraine triptans | Sumatriptan, rizatriptan | 5-HT1B/1D agonist | Acute migraine |

Psychedelic-Assisted Therapy

Psilocybin and other 5-HT2A agonists show promise in:

• Treatment-resistant depression: Phase 2 trials show rapid and sustained effects
• Anxiety and depression in cancer patients: FDA breakthrough therapy designation
• Addiction: Clinical trials for smoking cessation and alcohol use disorder
• Mechanism: Rapid neural plasticity through 5-HT2A activation and [mTOR](/entities/mtor) signaling[@ly2018]

Drug Development Challenges

• Hallucinogenic effects: Therapeutic use requires non-hallucinogenic analogs
• Cardiovascular effects: Peripheral 5-HT2A causes vasoconstriction
• Temporal dynamics: Receptor desensitization and internalization patterns

Key Publications

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Schizophrenia](/diseases/schizophrenia)
• [Depression](/diseases/depression)
• [Serotonin Signaling](/mechanisms/serotonin-signaling)
• [Cerebral Cortex](/cerebral-cortex)
• [Serotonin Receptors](/entities/serotonin-receptors)
• [Psychedelics](/therapeutics/psychedelic-therapy)

External Links

• [NCBI Gene: HTR2A](https://www.ncbi.nlm.nih.gov/gene/3352)
• [UniProt: HTR2A](https://www.uniprot.org/uniprot/P28223)
• [Ensembl: HTR2A](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102468)
• [Human Protein Atlas: HTR2A](https://www.proteinatlas.org/ENSG00000102468-HTR2A)
• [IUPHAR/BPS Guide to Pharmacology: 5-HT2A](https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=49)

Background

The study of Htr2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• [Allen Human Brain Atlas - HTR2A Expression](https://human.brain-map.org/microarray/search/show?search_term=HTR2A)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)

Expression Pattern

HTR2A shows region-specific expression in the brain:

High Expression:

• Cerebral cortex (layer 5 pyramidal neurons)
• Olfactory tubercle
• Nucleus accumbens
• Hippocampal interneurons

• Expressed primarily in glutamatergic pyramidal neurons
• Some expression in GABAergic interneurons
• Not expressed in dopaminergic or serotonergic cell bodies

Molecular Mechanisms

The 5-HT2A receptor is a GPCR coupled to Gq proteins, activating:

• Phospholipase C (PLC)
• Protein kinase C (PKC)
• Calcium signaling cascades
• MAPK/ERK pathway

• Neuronal excitability
• Neurotransmitter release
• Gene expression via transcription factors
• Dendritic spine morphology

Role in Neurodegeneration

Alzheimer's Disease:

• 5-HT2A receptor density reduced in AD cortex
• Role in Aβ-induced neurotoxicity
• Therapeutic target for behavioral symptoms

• Altered 5-HT2A signaling in PD psychosis
• Target for pimanserin (anti-psychotic)
• Modulates L-DOPA-induced dyskinesias

• 5-HT2A polymorphisms affect treatment response
• Antidepressant effects of 5-HT2A antagonism

Therapeutic Targeting

| Drug | Indication | Mechanism |
|------|------------|-----------|
| Pimavanserin | PD psychosis | 5-HT2A inverse agonist |
| Ketanserin | Research | 5-HT2A antagonist |
| DOI | Research | 5-HT2A agonist |

Animal Models

5-HT2A knockout mice show:

• Impaired sensorimotor gating
• Reduced anxiety-like behavior
• Altered psychedelic response

Research Directions

• Developing biased agonists with reduced side effects
• Understanding receptor heterodimerization
• Biomarker development for 5-HT2A dysfunction
• Role in neuroinflammation

References

Pathway Diagram

The following diagram shows the key molecular relationships involving HTR2A Gene discovered through SciDEX knowledge graph analysis: